Supernus Pharmaceuticals Inc (SUPN) US$0.001

Sell:$34.98Buy:$52.98$1.19 (2.55%)

NASDAQ:0.45%
Market closed |
Prices delayed by at least 15 minutes
Sell:$34.98
Buy:$52.98
Change:$1.19 (2.55%)
Deal now
Market closed |
Prices delayed by at least 15 minutes
Sell:$34.98
Buy:$52.98
Change:$1.19 (2.55%)
Market closed |
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.

Key people

Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
Timothy C. Dec
Chief Financial Officer, Senior Vice President
Frank Mottola
Chief Operating Officer, Chief Technology Officer
Padmanabh P. Bhatt
Senior Vice President - Intellectual Property, Chief Scientific Officer
Jonathan Rubin
Senior Vice President, Chief Medical Officer - Research and Development
Charles W. Newhall
Independent Chairman of the Board
Carrolee Barlow
Independent Director
Georges Gemayel
Independent Director
Frederick M. Hudson
Independent Director
Bethany L. Sensenig
Independent Director
Click to see more

Key facts

  • EPIC
    SUPN
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US8684591089
  • Market cap
    $2.59bn
  • Employees
    674
  • Shares in issue
    56.07m
  • Exchange
    NASDAQ
  • Index
    S&P 600 Small Cap, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.